CureDRPLA was a proud exhibitor at the International Congress of Parkinson's Disease and Movement Disorders in Copenhagen, held from August 27-31. This event drew in a remarkable crowd of over 5,200 in-person attendees representing more than 100 countries. This...
The FDA, the US regulatory agency for new medicines, declined to review the documents for a potential therapy for SCA3 (type of ataxia) developed by Biohaven. The criteria for approving a drug often rely on standards established for more prevalent conditions, making...
If you ever asked yourself this, the map we have created will come in handy. We coloured in orange those countries in which at least one person with DRPLA has been identified – 35 countries in total! We have gathered this information from scientific articles and...
On February 22nd, I organised a meet up for families affected by DRPLA who are based in Wales. I travelled to Cardiff with Dr Hector Garcia-Moreno and Ola Volhin, who work at University College London on the DRPLA Natural History and Biomarkers Study. We met with...
We interviewed Dr Hector Garcia-Moreno and Ola Volhin about the DRPLA Natural History and Biomarkers Study, watch the full interview here. This is a global study with sites in London, New York and North Carolina, all of which are currently recruiting participants. The...